Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis

Affiliations

¹ Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ghobbs@partners.org.

John R Bales et al. Bone Marrow Transplant. 2023 Apr.

. 2023 Apr;58(4):459-461.

doi: 10.1038/s41409-023-01913-9. Epub 2023 Jan 10.

¹ Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ghobbs@partners.org.

No abstract available

References

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. - DOI - PubMed
1. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management. Am J Hematol. 2021;96:145–62. - DOI - PubMed
1. Yoon J, Pettit K. Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions. Expert Rev Hematol. 2021;14:607–19. - DOI - PubMed
1. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl J Med. 2012;366:799–807. - DOI - PubMed - PMC
1. Shimomura Y, Hara M, Katoh D, Hashimoto H, Ishikawa T. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2018;97:1049–56. - DOI - PubMed